PT  - JOURNAL ARTICLE
AU  - Ji Young Hwang
AU  - Da Hee Kim
AU  - Hyo Sook Bae
AU  - Mi-La Kim
AU  - Yong Wook Jung
AU  - Bo Seong Yun
AU  - Seok Ju Seong
AU  - Eunah Shin
AU  - Mi Kyoung Kim
TI  - Combined Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment for Women With Grade 2 Stage IA Endometrial Cancer
AID  - 10.1097/IGC.0000000000000927
DP  - 2017 May 01
TA  - International Journal of Gynecologic Cancer
PG  - 738--742
VI  - 27
IP  - 4
4099  - http://ijgc.bmj.com/content/27/4/738.short
4100  - http://ijgc.bmj.com/content/27/4/738.full
SO  - Int J Gynecol Cancer2017 May 01; 27
AB  - Objective The aim of this study was to evaluate the oncologic and pregnancy outcomes of combined oral medroxyprogesterone acetate (MPA)/levonorgestrel-intrauterine system (LNG-IUS) treatment in young women with grade 2–differentiated stage IA endometrial adenocarcinoma who wish to preserve fertility.Methods We retrospectively reviewed the medical records of patients with grade 2 stage IA endometrial adenocarcinoma who had received fertility-sparing treatment at CHA Gangnam Medical Center between 2011 and 2015. All of the patients were treated with combined oral MPA (500 mg/d)/LNG-IUS, and follow-up dilatation and curettage were performed every 3 months.Results A total of 5 patients were included in the study. The mean age was 30.4 ± 5.3 years (range, 25–39 years). After a mean treatment duration of 11.0 ± 6.2 months (range, 6–18 months), complete response (CR) was shown in 3 of the 5 patients, with partial response (PR) in the other 2 patients. One case of recurrence was reported 14 months after achieving CR. This patient was treated again with combined oral MPA/LNG-IUS and achieved CR by 6 months. The average follow-up period was 44.4 ± 26.2 months (range, 12–71 months). There were no cases of progressive disease. No treatment-related complications arose.Conclusions Combined oral MPA/LNG-IUS treatment is considered to be a reasonably effective fertility-sparing treatment of grade 2 stage IA endometrial cancer. Although our results are encouraging, it is preliminary and should be considered with experienced oncologists in well-defined protocol and with close follow-up.